A structural study on uranyl (VI) nitrate complexes with cyclic amides: N-n-butyl-2-pyrrolidone, N-cyclohexylmethyl-2-pyrrolidone, and 1,3-dimethyl-2-imidazolidone
摘要:
Structural analyses Of UO2(NO3)(2)L-2 [L = N-n-butyl-2-pyrrolidone (NBP), N-cyclohexylmethyl-2-pyrrolidone (NCMeP), and 1,3dimethyl-2-imidazolidone (DMI)] have been carried out using X-ray diffraction method. These uranyl complexes were found to have a hexagonal bipyramidal structure. The bond distances (angstrom) of U=O and U-O(ligand), and bond angles (degrees) of U-O-C(carbonyl) are determined as follows: 1.774(2), 2.374(2), and 137.6(2) for UO2(NO3)(2)(NBP)(2); 1.770(l), 2.383(2), and 135.3(l) for UO2(NO3)(2)(NCMeP)(2); 1.771(2), 2.361(2), and 143.3(2) for UO2(NO3)(2)(DMI)(2)- In uranyl nitrate complexes with cyclic amides such as 2-pyrrolidone, urea, and caprolactam derivatives, a linear correlation was found to hold between U-O(ligand) bond distances and U O-C(carbonyl) bond angles. Vibrational frequencies Of UO2(NO3)(2)L-2 have also been measured by IR and Raman spectrophotometers. Using relationships between vibrational frequencies of O=U=O bonds and donor numbers (DNs) of ligands, it was found that donicities of N-substituted2-pyrrolidones (Me, Et, Bu, cyclohexyl, and cyclohexylmethyl) are in the range of 26-29, and the DN of 1,3-dimethyl-2-imidazolidone was estimated as 27.8. (c) 2005 Elsevier B.V. All rights reserved.
reactions of levulinicacid (LA), hydrogenation and reductiveamination with cyclohexylamine, were explored in a multiphase system composed of an aqueous solution of reactants, a hydrocarbon, and commercial 5 % Ru/C as a heterogeneous catalyst. By tuning the relative volume of the immiscible water/hydrocarbon phases and the concentration of the aqueous solution, a quantitative conversion of LA was achieved
在60–150°C和15–35 bar H 2的条件下,在由反应物,碳氢化合物和商业化的水溶液组成的多相体系中,探索了乙酰丙酸(LA)的两个模型反应,氢化反应和环己胺的胺化反应。 5%Ru / C作为非均相催化剂。通过调节不混溶的水/烃相的相对体积和水溶液的浓度,通过形成γ-戊内酯或N可以实现LA的定量转化-(环己基甲基)吡咯烷酮的选择性分别> 95和88%。此外,催化剂可以分离在烃相中,并以有效的半连续方案进行再循环。在这种条件下,甲酸添加剂通过在催化剂表面的竞争性吸附影响了LA的反应性。该效果对于提高还原胺化过程的选择性至关重要。5%Ru / C与一系列碳载体的比较表明,以前从未报道过的烃相中的偏析现象是pH依赖性的,并且对于显示中等表面酸度的样品有效。
Prophylactic/Therapeutic Agent for Diabetes
申请人:Cho Nobuo
公开号:US20090264650A1
公开(公告)日:2009-10-22
The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1):
wherein each symbol is as defined in the description,
or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.
The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1):
wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.